Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

NCT00000933 · View on ClinicalTrials.gov ↗

Study Summary

Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the presence of drugs used to kill them). The purpose of this study is to see if people who take azithromycin carry more antibiotic-resistant bacteria than people who have chosen to delay MAC preventive therapy. When bacteria like Streptococcus (a type of bacteria that causes pneumonia and meningitis) are frequently exposed to antibiotics, the bacteria can become resistant to the drugs. MAC preventive therapy uses antibiotics, but this can make it difficult to treat other infections caused by bacteria that have become resistant in HIV-infected persons. If MAC preventive therapy is delayed, Streptococcus in the body may be less likely to develop resistance. Therefore, if the patient does get a Streptococcus infection, it will be easier to treat because it is not resistant to the antibiotics.

Study Locations (15)

Michigan

  • Wayne State Univ - WSU/DMC / Univ Hlth Ctr — Detroit
  • Henry Ford Hosp — Detroit

New Jersey

  • Southern New Jersey AIDS Cln Trials / Dept of Med — Camden
  • North Jersey Community Research Initiative — Newark

California

  • Community Consortium / UCSF — San Francisco

Colorado

  • Denver CPCRA / Denver Public Hlth — Denver

District of Columbia

  • Washington Reg AIDS Prog / Dept of Infect Dis — Washington D.C.

Georgia

  • AIDS Research Consortium of Atlanta — Atlanta

Illinois

  • AIDS Research Alliance - Chicago — Chicago

Louisiana

  • Louisiana Comm AIDS Rsch Prog / Tulane Univ Med — New Orleans

Trial Details

FieldValue
Enrollment Target 326 participants
Est. Completion 2000-07

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000933

The ClinicalTrials.gov registry entry for NCT00000933 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00000933 reports 15 study locations spanning 13 distinct geographic areas — top geographies include Michigan, New Jersey, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00000933 about?

NCT00000933 is a clinical study titled "Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048". Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the presence of drugs used to kill them). The purpose of this study is to see if ...

What is the current status of trial NCT00000933?

This trial is currently completed. The enrollment target is 326 participants. Estimated completion is 2000-07.

What conditions does trial NCT00000933 study?

This clinical trial studies the following conditions: HIV Infections, Pneumococcal Infections, Mycobacterium Avium-intracellulare Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT00000933?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00000933 being conducted?

This trial has 15 study locations across California, Colorado, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial